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ABSTRACT
The significance of blood cultures positive for
emerging saprophytic moulds (e.g., Scedosporium
apiospermum, Scedosporium prolificans, Paecilomyces
spp.) was evaluated in 30 cancer patients (1996–
2002). Diagnostic criteria proposed previously for
evaluation of aspergillaemia were used. Blood
cultures positive for emerging saprophytic
moulds represented 1% of all positive fungal
cultures. One case of catheter-related fungaemia
was excluded. The remaining 29 cases consisted
of true (n = 5), probable (n = 1), indeterminate
(n = 7) fungaemia, and contamination (n = 16).
True fungaemia was seen only in leukaemia
patients and allogeneic bone marrow transplant
recipients. S. apiospermum and S. prolificans were
the commonest causes of true fungaemia.
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Invasive mould infections (IMIs) have emerged as
a significant cause of death in leukaemia patients
and allogeneic bone marrow transplant (BMT)
recipients [1, 2]. Although pneumonia is the
commonest clinical presentation, bloodstream
dissemination to organs other than the lungs
may occur [1–3]. Aspergillus spp. are the com-
monest moulds causing IMIs, but are isolated
rarely from blood specimens [3]. In contrast,
Fusarium spp., the second most common oppor-
tunistic moulds in some institutions, are isolated
from 60–70% of blood specimens from patients
with disseminated fusariosis [4]. Several less
common moulds, including Scedosporium apiosper-
mum, Scedosporium prolificans, Alternaria spp. and
Paecilomyces spp., have been implicated increas-
ingly in IMIs, including fungaemia [4–6].
Except for central venous catheter (CVC)-rela-
ted cases of fungaemia, determining the signifi-
cance of blood cultures positive for moulds from
cancer patients is challenging, as contamination of
blood culture media may occur, yielding false-
positive results [3]. Therefore, the present study
evaluated the frequency and significance of such
cultures in unselected cancer patients over a
7-year period.
Laboratory records were reviewed for patients
with mould-positive blood cultures during the
period January 1996 to May 2002. Blood culture
analysis was performed with the BACTEC 9240
system with BACTEC Plus Aerobic F medium
(BD Microbiology Systems, Sparks, MD, USA)
and the Isolator 10 system (Wampole, Cranbury,
NJ, USA) [7]. Standard morphological criteria
were used for mould identification [8]. To deter-
mine the significance of mould-positive blood
cultures, the medical records of patients were
reviewed for underlying malignancy and risk
factors, clinical and radiographical signs of IMI,
number of mould-positive cultures, antifungal
treatment and outcome.
Diagnostic criteria described previously for
Aspergillus fungaemia were used to diagnose
definite fungaemia, probable fungaemia and
blood specimen contamination caused by emer-
ging saprophytic moulds [9]. A category of
indeterminate fungaemia was introduced for
cases that met the probable fungaemia criteria
but yielded other pathogens concomitantly from
the blood (and ⁄ or lower respiratory tract in cases
of pneumonia). Finally, CVC-related fungaemia
was defined as mould isolation from the blood
with tenderness and redness at a catheter site
without evidence of IMI [10]. Patients excluded
from the study were those with Aspergillus- and
Fusarium-positive blood cultures, as their signifi-
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cance has been studied previously [3,4], and those
with CVC-related infections.
Identification of all true-positive cases is
required to calculate the positive predictive value
(PPV) for statistical groups. However, the total
number of true-positive fungaemia cases could
not be defined because the numbers of patients
with true fungaemia in the probable and indeter-
minate groups were unknown. Hence, PPVs were
calculated using four analytical models for the
number of true-positive (numerator) and true-
positive plus false-positive cultures (denomin-
ator) as described previously [11]. Categorical
data were analysed using the two-tailed Fisher
exact test, with p values < 0.05 considered to be
statistically significant.
In total, 185 000 blood cultures were processed
during the study period. Moulds other than
Aspergillus and Fusarium spp. were isolated from
44 specimens (from 30 patients), representing
0.02% of all specimens, 0.1% of all positive
blood cultures, and 1% of all positive fungal
blood cultures (Table 1). There was no tem-
poral or spatial clustering of mould-positive
blood cultures. One patient with CVC-related
Aureobasidium pullulans fungaemia was excluded.
Eighteen of those remaining had leukaemia or
had received an allogeneic BMT, while 11 had a
solid tumour. The median age was 48 years
(range 8–76 years); 16 patients were male.
Six patients (20%) had either definite (n = 5) or
probable (n = 1) fungaemia, seven (24%) had
indeterminate fungaemia, and cultures from 16
(55%) were contaminated. All patients with
definite or probable fungaemia had leukaemia
or had received an allogeneic BMT, representing
33% of the 18 fungaemic patients in that group.
No patients with solid tumours and mould-
positive cultures had definite or probable fung-
aemia; all 11 cultures represented contamination
(p < 0.05). Hence, the PPV of mould-positive
blood cultures in solid tumour patients was 0%,
irrespective of the analytical model, but ranged
from 28% to 72% in leukaemia patients and ⁄ or
allogeneic BMT recipients (Table 2).
Definite fungaemia was caused most often
by Scedosporium spp. (S. apiospermum, n = 3;
S. prolificans, n = 1), compared with one fungae-
mia case caused by all other moulds combined
(p < 0.01) (Table 1). Thus, in leukaemia patients
and ⁄ or allogeneic BMT recipients, the PPV of
Scedosporium-positive cultures (80%) was higher
than that of non-Scedosporium-positive cultures
(8–69%; Table 2). All five patients with definite
fungaemia died; the mould from each of these
patients was cultured ante-mortem. In the three
episodes of definite S. apiospermum fungaemia, the
cultures became positive 1–10 days before death.
Three patients had autopsy-proven involvement
of the lungs, lungs and orbit, and lungs and skin,
respectively. In all three patients, blood cultures
became positive 6–10 days after the first clinical
and radiographical IMI findings. In the case of
definite S. prolificans fungaemia, the culture
Table 1. Significance of blood cultures positive for emerging saprophytic moulds in patients with cancer
Mould isolated (no. of patients)
Fungaemia category Risk factor
Definitea Probablea Indeterminateb Contaminationa
Haematological
malignancy and/or
allogeneic BMTc,d
Solid
tumourc,d
Scedosporium moulds (5)e,f 4 0 0 1 5 0
S. apiospermum (4) 3 0 0 1 4 0
S. prolificans (1) 1 0 0 0 1 0
Non-Scedosporium moulds (24)e,f 1 1 7 15 13 11
Aureobasidium pullulans (14) 0 1 3 10 6 8
Paecilomyces spp. (4) 1 0 2 1 3 1
Alternaria spp. (3) 0 0 2 1 2 1
Other moulds (3)g 0 0 0 3 2 1
Total number of patients
with positive blood cultures (29)
5 1 7 16 18 11
aDiagnosis of definite and probable fungaemia and contamination by a mould [9].
bCases meeting the criteria for probable fungaemia, but with other pathogens recovered concomitantly from the blood and ⁄ or lower respiratory tract. In the seven patients
with indeterminate fungaemia, Gram-positive cocci (n = 4), Gram-negative bacilli (n = 4) and cytomegalovirus-positive antigenaemia (n = 1) were associated with possible
fungaemia. In two patients, multiple co-pathogens were cultured.
cp < 0.05 in contamination cases in high-risk patients vs. patients with a solid tumour.
dp < 0.05 in definite and probable fungaemia cases in high-risk patients vs. patients with a solid tumour.
ep < 0.01 in definite Scedosporium fungaemia cases vs. Scedosporium contamination cases.
fp < 0.01 in definite Scedosporium fungaemia cases vs. definite fungaemia cases caused by all other non-Scedosporium moulds combined.
gTrichoderma, Bipolaris and Chaetomium spp., respectively.
Research Note 923
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 922–950
became positive on the day fever began, 10 days
before death. This patient had autopsy-verified
involvement of the lungs, stomach and orbit. In
the definite case of Paecilomyces fungaemia, the
mould was cultured 39 days ante-mortem; aut-
opsy revealed lung involvement. The blood cul-
ture became positive 1 day after fever initiation,
but 2 weeks before radiographical evidence of
pneumonia.
In only two (7%) patients with leukaemia and
autopsy-verified disseminated infection was a
mould cultured more than once. These patients
had autopsy-verified involvement of the lung,
stomach and orbit, and lung and skin, respect-
ively. In 14 (48%) and 13 (45%) patients, the
mould was cultured only from peripheral and
CVC-drawn blood, respectively. In the remaining
two patients, the mould (S. apiospermum and
S. prolificans, respectively) was isolated from both
sources; both of these patients had definite fung-
aemia. There were no differences in the PPV of
mould-positive cultures from peripheral vs. CVC-
drawn blood.
Current culture methods used for timely IMI
diagnosis lack sensitivity, specificity and ade-
quate predictive value, even for high-risk patients
[1–3]. Determining the significance of blood cul-
tures positive for rare yet emerging saprophytic
moulds is especially complicated, as their natural
history is undefined. This is the first study to
apply criteria proposed previously for aspergill-
aemia [9] to differentiation of true fungaemia
caused by such moulds from blood culture
contamination in unselected cancer patients.
The study had certain limitations. First,
although stringent diagnostic criteria were used,
the possibility cannot be excluded that some
indeterminate fungaemias, or even some cases
with positive blood cultures deemed to represent
contamination, represent classification error. Also,
because of the small case number, the PPV of
positive cultures should be viewed cautiously.
Moreover, because only cancer patients were
studied, the findings should not necessarily be
extrapolated to other groups of immunocompro-
mised patients. Nevertheless, definite or probable
fungaemia appeared uncommon (20% true-posit-
ive blood cultures), and occurred exclusively in
patients at highest risk for IMIs. Conversely, all
mould-positive cultures from patients with solid
tumours were false-positives. This agrees with
previous experience with Aspergillus-positive
blood cultures from patients with solid tumours
[3]. Recovery of Scedosporium spp. from the blood
of high-risk patients indicated true infection, and
the PPV of such cultures agreed with that reported
previously [4, 12], but 66% of mould-positive
blood cultures in high-risk patients represented
contamination or indeterminate fungaemia.
Hence, even in high-risk patients, the significance
of saprophytic mould isolation from blood, espe-
cially of non-Scedosporium spp., is unclear. There-
fore, careful clinical assessment is recommended
before antifungal treatment. The high proportion
of cultures representing contamination or indeter-
minate fungaemia in high-risk patients may affect
the diagnostic accuracy of more sensitive tech-
niques, such as pan-fungal PCR [3]. Such tests,
especially if they represent isolated findings,
could signify contamination.
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ABSTRACT
The efficacy of voriconazole in combination with
amphotericin B or micafungin was studied in a
transiently neutropenic guinea-pig model of inva-
sive pulmonary aspergillosis. Guinea-pigs treated
with the antifungal drugs, alone or in two-drug
combinations, had an improved survival rate and
reduced fungal burden in the lungs compared
to untreated control animals. The efficacy of
monotherapy and combination therapy was sim-
ilar; activity was neither enhanced nor reduced
with the two-drug combinations. Further studies
of efficacy, dosing and optimal regimens for
antifungal combinations are warranted.
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Invasive aspergillosis is an escalating clinical
problem with high mortality [1–3]. The standard
drugs for treatment include amphotericin B (or its
lipid form) and itraconazole, but neither agent is
totally effective [3]. Voriconazole has been
approved recently in the USA for the treatment
of invasive aspergillosis, and has a response rate
of c. 50% [4]. Caspofungin acetate, a new anti-
fungal agent in the echinocandin family, has been
shown to be effective in c. 40% of patients with
refractory aspergillosis [5]. Given this sub-optimal
outcome with antifungal monotherapy, an attract-
ive option is a combination of drugs from differ-
ent classes with distinct target sites.
In-vitro data suggest that the activity of anti-
fungal combinations of an azole plus polyene,
azole plus echinocandin, or polyene plus echino-
candin, against aspergillosis may range from an
additive effect to synergism [6–8]. Data from
animal studies are sparse [9], but the superior
efficacy of voriconazole over amphotericin B has
been demonstrated previously in a transiently
neutropenic guinea-pig model of invasive pul-
monary aspergillosis [10]. With the same model,
the present study evaluated the efficacy of a
reduced dose of voriconazole in combination with
amphotericin B or micafungin (an echinocandin).
The Aspergillus fumigatus strain used in this
study, W73355 (ATCC 208996), was a clinical
isolate obtained from the Detroit Medical Center.
This organism was susceptible to amphotericin B,
voriconazole (MICs of 0.5 mg ⁄L and 0.25 mg ⁄L,
respectively) and micafungin (minimal effective
concentration 0.03 mg ⁄L). Working cultures were
maintained on Sabouraud dextrose agar slants at
4C. The drugs used were amphotericin B deo-
xycholate (Fungizone; Bristol Meyers Squibb,
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